Research and Markets has announced the addition of the "World Generic Markets Issue 277 (V15 I10)" report to their offering.
Until recently there has been no correlation evident between ANDA approvals and the GDUFA programme. However, a significant increase in final approvals in 2015, may prove to be the results of GDUFA's impact on the industry. If so, further substantial increases in 2016 and beyond can be expected. The increase in overall approvals is juxtaposed by a decrease in first-time approvals; efforts to reverse this trend must be considered to preserve a healthy generic industry.
Key Topics Covered:
- Aurobindo Gains FDA Tranexamic Acid Approval
- FDA Accepts Amgen's Biosimilar Adalimumab For Review
- Perrigo Completes Generic Tretinoin Portfolio Acquisition
- Amneal, Aurobindo Gain FDA Paricalcitol Approvals
- Granules Enters OTC Omeprazole Agreement With Par
- Aurobindo Gains FDA Voriconazole Approval
- Dr Reddy's Gains FDA Sumatriptan Approval
- Dr Reddy's Receives Doxycycline Tentative Approval
- Sun Launches Imatinib Mesylate In US
- Muted Pressure On Generic Pricing To Be Expected
- ANI Acquires Three Generics From H2-Pharma
- Impax Gains Tentative Ezetimibe+Simvastatin Approval
- Teligent Gains Lidocaine Approval
- Gilead In Strong Position To Counter TAF Lawsuit
- Eagle Launches Alcohol-Free Docetaxel
- Resumption Of Trade Talks Will Be Litmus Test For EU
- Market Conditions Challenge Sandoz But Biosimilars Provide Optimism
- Biocad's Trastuzumab Approved In Russia
- Lek Opens New Laboratory In Menges
- Sub-Licences Put MPP On The Cusp Of New Era
- Richter Acquires Joint Venture Partner In China
- Compulsory Licence Rejection Will Secure Onglyza Emerging Market Sales
- Kyowa Hakko Kirin Enters Rituximab Agreement With Sandoz
- Positive Phase III Results Reported For CHS-0214
For more information visit http://www.researchandmarkets.com/research/m2hv34/world_generic
View source version on businesswire.com: http://www.businesswire.com/news/home/20160621005933/en/
Contacts:
Laura Wood, Senior Manager
press@researchandmarkets.com
For
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S.
Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Generic
Drugs
